title: Anti-CRLF2 Antibody-Armored Biodegradable Nanoparticles for Childhood B-ALL.
abstract: B-precursor acute lymphoblastic leukemia (B-ALL) lymphoblast (blast) internalization of anti-cytokine receptor-like factor 2 (CRLF2) antibody-armored biodegradable nanoparticles (AbBNPs) are investigated. First, AbBNPsaere synthesized by adsorbing anti-CRLF2 antibodies to poly(D,L-lactide-co-glycolide) (PLGA) nanoparticles of various sizes and antibody surface density (Ab/BNP) ratios. Second, AbBNPs are incubated with CRLF2-overexpressing (CRLF2+) or control blasts. Third, internalization of AbBNPs by blasts is evaluated by multicolor flow cytometry as a function of receptor expression, AbBNP size, and Ab/BNP ratio. Results from these experiments are con-firmed by electron microscopy, fluorescence microscopy, and Western blotting. The optimal size and Ab/BNP for internalization of AbBNPs by CRLF2+ blasts is 50 nm with 10 Ab/BNP and 100 nm with 25 Ab/BNP. These studies show that internalization of AbBNPs in childhood B-ALL blasts is AbBNP size-and Ab/BNP ratio-dependent. All AbBNP combinations are non-cytotoxic. It is also shown that CD47 is very slightly up-regulated by blasts exposed to AbBNPs. CD47 is "the marker of self" overexpressed by blasts to escape phagocytosis, or "cellular devouring", by beneficial macrophages. The results indicate that precise engineering of AbBNPs by size and Ab/BNP ratio may improve the internalization and selectivity of future biodegradable nanoparticles for the treatment of leukemia patients, including drug-resistant minority children and Down's syndrome patients with CRLF2+B-ALL.
authors: Pediatric Biochemistry Laboratory Department of Chemistry-BSE 3.108A University of Texas at San Antonio One UTSA Circle, San Antonio, TX 78249, USA.
authors: Rekha
authors: R
authors: Raghunathan
authors: Swetha
authors: S
authors: Mahesula
authors: Kranthi
authors: K
authors: Kancharla
authors: Preethi
authors: P
authors: Janardhanan
authors: Yeshwant L A
authors: YL
authors: Jadhav
authors: Robert
authors: R
authors: Nadeau
authors: German P
authors: GP
authors: Villa
authors: Robert L
authors: RL
authors: Cook
authors: Colleen M
authors: CM
authors: Witt
authors: Jonathan A L
authors: JA
authors: Gelfond
authors: Thomas G
authors: TG
authors: Forsthuber
authors: William E
authors: WE
authors: Haskins
references: Blood. 2006 Mar 15;107(6):2548-56
references: 16291597
references: J Immunol. 1983 Nov;131(5):2458-67
references: 6415171
references: Blood. 2010 Feb 4;115(5):1006-17
references: 19965641
references: Eur J Pharm Biopharm. 2011 Jan;77(1):26-35
references: 21093589
references: EMBO J. 2006 Nov 29;25(23):5560-8
references: 17093498
references: In Vitro. 1974 Mar-Apr;9(5):303-10
references: 4523807
references: Proc Natl Acad Sci U S A. 2009 Jun 9;106(23):9414-8
references: 19470474
references: Proc Natl Acad Sci U S A. 2012 Apr 24;109(17):6662-7
references: 22451913
references: Int J Pharm. 2003 Apr 30;256(1-2):141-52
references: 12695020
references: Blood. 2002 Sep 15;100(6):1957-64
references: 12200352
references: Crit Rev Oncog. 2011;16(1-2):13-24
references: 22150304
references: Semin Oncol. 2004 Dec;31(6 Suppl 13):16-35
references: 15717736
references: N Engl J Med. 2010 Sep 16;363(12):1117-27
references: 20843246
references: Science. 2000 Jun 16;288(5473):2051-4
references: 10856220
references: Int J Pharm. 2009 Feb 9;367(1-2):195-203
references: 18940242
references: Blood. 2010 Feb 18;115(7):1394-405
references: 19880498
references: Br J Haematol. 1995 Apr;89(4):771-9
references: 7539624
references: Rev Panam Salud Publica. 2005 Jul;18(1):5-13
references: 16105320
references: Proc Natl Acad Sci U S A. 2010 Nov 9;107(45):19455-60
references: 20974963
references: J Mol Biomark Diagn. 2010;1(1):
references: 23487404
references: Chem Soc Rev. 2012 Apr 7;41(7):2545-61
references: 22334259
references: Mol Cell Proteomics. 2012 Jun;11(6):M112.017764
references: 22345495
references: J Control Release. 2008 Jun 4;128(2):120-7
references: 18436327
references: Nat Nanotechnol. 2008 Mar;3(3):145-50
references: 18654486
references: Cell. 2010 Sep 3;142(5):699-713
references: 20813259
references: Blood. 2008 Nov 15;112(10):4259-67
references: 18779391
references: Cancer. 2006 Oct 15;107(8):1711-42
references: 16958083
references: Blood. 2009 Sep 24;114(13):2688-98
references: 19641190
references: Blood Cells Mol Dis. 2010 Jun 15;45(1):67-74
references: 20299253
references: J Control Release. 2007 Jul 16;120(1-2):18-26
references: 17509712
references: Biochem J. 2004 Jan 1;377(Pt 1):159-69
references: 14505488
references: J Pharm Sci. 1995 Apr;84(4):493-8
references: 7629743
references: Drug Metab Dispos. 1986 May-Jun;14(3):349-52
references: 2872037
references: Pharm Res. 2002 Aug;19(8):1137-43
references: 12240939
references: J Immunol. 2008 Jun 15;180(12):8073-82
references: 18523271
references: NeuroRx. 2005 Jan;2(1):108-19
references: 15717062
references: Leuk Lymphoma. 2004 Jul;45(7):1319-27
references: 15359629
references: Mol Vis. 2003 Oct 15;9:559-68
references: 14566223
references: J Exp Med. 2012 Feb 13;209(2):259-73
references: 22271575
references: Blood. 2010 Jul 1;115(26):5312-21
references: 20139093
references: J Nanobiotechnology. 2011 Nov 28;9:55
references: 22123084
references: J Clin Oncol. 2000 Feb;18(4):813-23
references: 10673523
references: Cancer Chemother Pharmacol. 1996;38(4):373-7
references: 8674161
references: Cancer Chemother Pharmacol. 1994;34(3):230-4
references: 8004756
references: Leukemia. 2012 Feb;26(2):255-64
references: 21869836
references: Trends Immunol. 2008 May;29(5):203-6
references: 18394962
references: Nat Rev Drug Discov. 2007 Feb;6(2):149-65
references: 17268486
references: PLoS One. 2012;7(3):e34019
references: 22442740
references: J Control Release. 1998 Mar 2;52(1-2):53-62
references: 9685935
references: Cancer Res. 2010 Oct 1;70(19):7347-52
references: 20807819
references: Biochim Biophys Acta. 2003 Jan 10;1609(1):102-8
references: 12507764
references: Clin Vaccine Immunol. 2011 Feb;18(2):210-6
references: 21177916
references: Clin Cancer Res. 2011 Dec 1;17(23):7347-58
references: 21976548
references: Cancer Res. 2011 Feb 15;71(4):1374-84
references: 21177380